A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19
Public safety concern of the ChAdOx1 vaccine has led to an alternative immunisation strategy against SARS-CoV-2, with this heterologous schedule widely adopted and officially recommended in many countries. Here, the authors report the immunogenicity and safety outcomes of heterologous prime-boost im...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-33146-7 |
| _version_ | 1811267623361445888 |
|---|---|
| author | Chih-Jung Chen Lan-Yan Yang Wei-Yang Chang Yhu-Chering Huang Cheng-Hsun Chiu Shin-Ru Shih Chung-Guei Huang Kuan-Ying A. Huang |
| author_facet | Chih-Jung Chen Lan-Yan Yang Wei-Yang Chang Yhu-Chering Huang Cheng-Hsun Chiu Shin-Ru Shih Chung-Guei Huang Kuan-Ying A. Huang |
| author_sort | Chih-Jung Chen |
| collection | DOAJ |
| description | Public safety concern of the ChAdOx1 vaccine has led to an alternative immunisation strategy against SARS-CoV-2, with this heterologous schedule widely adopted and officially recommended in many countries. Here, the authors report the immunogenicity and safety outcomes of heterologous prime-boost immunisation with ChAdOx1 and a spike-2P subunit vaccine in a single-blinded, randomised trial. |
| first_indexed | 2024-04-12T21:07:16Z |
| format | Article |
| id | doaj.art-734b5924f58149d382b1e865987a8a9d |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-12T21:07:16Z |
| publishDate | 2022-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-734b5924f58149d382b1e865987a8a9d2022-12-22T03:16:41ZengNature PortfolioNature Communications2041-17232022-09-0113111010.1038/s41467-022-33146-7A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19Chih-Jung Chen0Lan-Yan Yang1Wei-Yang Chang2Yhu-Chering Huang3Cheng-Hsun Chiu4Shin-Ru Shih5Chung-Guei Huang6Kuan-Ying A. Huang7Division of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial HospitalClinical Trial Center, Chang Gung Memorial FoundationClinical Trial Center, Chang Gung Memorial FoundationDivision of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial HospitalDivision of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial HospitalResearch Center for Emerging Viral Infections, College of Medicine, Chang Gung UniversityDepartment of Laboratory Medicine, Linkou Chang Gung Memorial HospitalDivision of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial HospitalPublic safety concern of the ChAdOx1 vaccine has led to an alternative immunisation strategy against SARS-CoV-2, with this heterologous schedule widely adopted and officially recommended in many countries. Here, the authors report the immunogenicity and safety outcomes of heterologous prime-boost immunisation with ChAdOx1 and a spike-2P subunit vaccine in a single-blinded, randomised trial.https://doi.org/10.1038/s41467-022-33146-7 |
| spellingShingle | Chih-Jung Chen Lan-Yan Yang Wei-Yang Chang Yhu-Chering Huang Cheng-Hsun Chiu Shin-Ru Shih Chung-Guei Huang Kuan-Ying A. Huang A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19 Nature Communications |
| title | A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19 |
| title_full | A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19 |
| title_fullStr | A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19 |
| title_full_unstemmed | A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19 |
| title_short | A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19 |
| title_sort | randomized controlled trial of heterologous chadox1 ncov 19 and recombinant subunit vaccine mvc cov1901 against covid 19 |
| url | https://doi.org/10.1038/s41467-022-33146-7 |
| work_keys_str_mv | AT chihjungchen arandomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT lanyanyang arandomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT weiyangchang arandomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT yhucheringhuang arandomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT chenghsunchiu arandomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT shinrushih arandomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT chunggueihuang arandomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT kuanyingahuang arandomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT chihjungchen randomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT lanyanyang randomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT weiyangchang randomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT yhucheringhuang randomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT chenghsunchiu randomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT shinrushih randomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT chunggueihuang randomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 AT kuanyingahuang randomizedcontrolledtrialofheterologouschadox1ncov19andrecombinantsubunitvaccinemvccov1901againstcovid19 |